NICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in England, ahead of a rival therapy from Alnylam.
Alnylam is to file its givosiran with regulators to treat a form of the blood disease porphyria, applying its gene silencing technology to the condition for the first time, following suppor
Some good news for the UK industry in turbulent times is always welcome, and several announcement this month showed us why the biotech sector in the country is looking extremely promising g
Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (C
Sanofi and Alnylam have agreed to conclude the research and option phase of their 2014 RNAi therapeutics alliance for developing drugs for rare genetic diseases.
